Abstract:<article><section><h2>Abstract</h2><h3> Background</h3><p>Teduglutide reduces or eliminates parenteral support (PS) dependency in patients with short bowel syndrome (SBS). Recent post hoc analyses demonstrated that effects are correlated with baseline PS volume. We assessed the SBS‐related quality‐of‐life (QoL) impact of teduglutide, particularly whether improvements are greater among subgroups achieving more PS volume reduction.</p><h3> Methods</h3><p>Using phase 3 trial data of teduglutide in patients with SBS (NCT00798967), change in Short Bowel Syndrome–Quality of Life (SBS‐QoL) scores from baseline were compared between teduglutide vs placebo in the overall population and subgroups classified by baseline PS volume requirement, disease etiology, and bowel anatomy. Generalized estimating equation models were fitted to assess impact of teduglutide on SBS‐related QoL using data from all visits, adjusted for baseline characteristics.</p><h3> Results</h3><p>Of 86 patients, 43 each were randomized to teduglutide or placebo (mean age: 51 vs 50 years, respectively). In adjusted analyses, teduglutide had a nonsignificant reduction (improvement) of −8.6 points (95% CI: 2.6 to −19.8) in SBS‐QoL sum score from baseline to Week‐24 vs placebo. The impact of teduglutide varied by subgroup. Patients treated with teduglutide experienced significantly greater reductions in SBS‐QoL sum score at Week‐24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (−27.3, 95% CI: −50.8 to −3.7) and inflammatory bowel disease (IBD; −29.6, 95% CI: −46.3 to −12.9). Results were similar for SBS‐QoL subscale and item scores.</p><h3> Conclusions</h3><p>The impact of teduglutide treatment on SBS‐related QoL vs placebo varied among subgroups and was significant and most pronounced among patients with highest baseline PS volume requirement or IBD.</p></section><section><h2> Clinical Relevancy Statement</h2><p>Parenteral support (PS) dependency in patients with short bowel syndrome and intestinal failure (SBS‐IF) has a significant impact on quality of life (QoL). Teduglutide reduces the PS volume requirement and, in some patients, assists PS independence. However, treatment response and teduglutide's impact on QoL may vary depending on the etiology, bowel anatomy, and PS volume requirement. This analysis explored teduglutide's impact on QoL in subgroups of patients with SBS‐IF defined by these characteristics and found that QoL improvements were most pronounced among patients with the highest PS volume requirements or inflammatory bowel disease.</p><h2> Introduction</h2><p>Short bowel syndrome (SBS) is a rare malabsorption disorder of the gastrointestinal (GI) tract related to conditions such as inflammatory bowel disease (IBD), mesenteric ischemia, or cancer.<span><a href="#jpen1588-bib-0001">1</a></span> Many patients with SBS rely on parenteral support (PS) for nutrient and fluid supplementation and consequently suffer from intestinal failure (IF).<span><a href="#jpen1588-bib-0002">2</a>, <a href="#jpen1588-bib-0003">3</a></span> The prevalence of IF is estimated to be 3–4 per million people in the United States<span><a href="#jpen1588-bib-0004">4</a></span> and about 5–20 per million people in Europe.<span><a href="#jpen1588-bib-0001">1</a>, <a href="#jpen1588-bib-0003">3</a>, <a href="#jpen1588-bib-0005">5</a></span> As a result of inadequate absorption of nutrients, fluid, and electrolytes, patients with IF associated with SBS (SBS‐IF) may experience complications that incur additional healthcare burden and negatively impact patients' quality of life (QoL).<span><a href="#jpen1588-bib-0006">6</a>-<a href="#jpen1588-bib-0009">9</a></span> Although PS may be lifesaving, it is also associated with lifestyle disruptions and potentially severe complications that negatively impact QoL and may increase mortality risk.<span><a href="#jpen1588-bib-0010">10</a>-<a href="#jpen1588-bib-0018">18</a></span> Thus, alleviation of malabsorption and PS reduction and weaning is a major clinical goal in the treatment of SBS‐IF patients with PS dependency. </p><p>Teduglutide, a glucagon‐like peptide‐2 analogue,<span><a href="#jpen1588-bib-0019">19</a></span> has been approved in the United States and Europe to reduce PS dependency for patients with SBS‐IF.<span><a href="#jpen1588-bib-0020">20</a>, <a href="#jpen1588-bib-0021">21</a></span> Association between PS volume reduction and SBS‐related QoL improvement was first evaluated using the phase 3 Study of Teduglutide Effectiveness in PS‐Dependent SBS Subjects (STEPS) trial.<span><a href="#jpen1588-bib-0017">17</a></span> Although that study reported statistically significant improvement in the Short Bowel Syndrome–Quality of Life (SBS‐QoL)<span><a href="#jpen1588-bib-0022">22</a></span> scores at Week‐24 compared with baseline in patients treated with teduglutide, there were no statistically significant di <p>-Abstract Truncated-</p>

Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy

P431 Teduglutide Use and Nutritional Outcomes in Short Bowel Syndrome with Intestinal Failure: a Real-World Claims Database Analysis

Intestinal adaptation and rehabilitation in adults with short bowel syndrome

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals

Teduglutide for pediatric short bowel syndrome patients

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study

Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

Long‐term teduglutide associated with improved response in pediatric short bowel syndrome‐associated intestinal failure

Teduglutide-induced acute gastric mucosal necrosis in short bowel syndrome with hepatorenal failure: Case report

Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (Teduglutide) - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome

Emerging treatments for short bowel syndrome in adult patients

S92 Successful Use of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Short Gut Syndrome in Patients With Inflammatory Bowel Disease

Prescribing Practice and Evaluation of Appropriateness of Enteral Nutrition in a University Teaching Hospital

Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome

Population pharmacokinetics and exposure‐response analyses of teduglutide in adult and pediatric patients with short bowel syndrome

Teduglutide improves liver chemistries in short bowel syndrome–associated intestinal failure: Post hoc analysis

Effects of Bowel Rehabilitation and Combined Trophic Therapy on Intestinal Adaptation in Short Bowel Patients.

Retrospective review of growth in pediatric intestinal failure after weaning from parenteral nutrition

Evaluation of the Effectiveness of Teduglutide Treatment in Patients with Short Bowel Syndrome in Slovakia—Multicenter Real-World Study

Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency

Cholecystitis following the initiation of glucagon‐like peptide‐2 analogue for short bowel syndrome: A case report